NCT04567524View on ClinicalTrials.gov

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Schizophrenia Schizoaffective
Interventions
DRUG

LYN-005

LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.

Trial Locations (5)

30331

Atlanta Center for Medical Research, Atlanta

75080

Pillar Clinical Research, LLC, Richardson

78754

Community Clinical Research, Inc, Austin

90806

Collaborative Neuroscience Research, LLC, Long Beach

08053

Hassman Research Institute, Marlton

Sponsors

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Lyndra Inc.

INDUSTRY